GlassScriptPhysician profile
James F Conrad
NPI 1982639191
$2,414.16
in general payments reported to CMS, 2019-2025
15 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $133 · 2021: $370 · 2022: $311 · 2023: $563 · 2024: $287 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,334.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $886.55 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $345.71 | 2023-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $177.93 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $165.97 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $121.84 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $109.77 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $105.82 | 2022-2024 | Vyzulta, Infuse, Miebo |
| Tarsus Pharmaceuticals, INC. | $103.27 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $94.33 | 2022-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $78.71 | 2019-2020 | |
| Biotissue Holdings INC. | $70.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $59.78 | 2019-2022 | |
| Harrow Eye, LLC | $36.58 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $31.71 | 2022-2024 | Dextenza |
| Dompe US, INC. | $25.22 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Conrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.